Effectiveness of acupuncture for cancer-related fatigue: a systematic reviews and meta-analysis - Summary - MDSpire

Effectiveness of acupuncture for cancer-related fatigue: a systematic reviews and meta-analysis

Share

Objective:

To evaluate the effectiveness of acupuncture for cancer-related fatigue (CRF) and update the strength of evidence.

Key Findings:
  • The meta-analysis included 28 RCTs with low overall study quality.
  • Acupuncture significantly improved fatigue levels compared to the control group (MD = -0.56, 95% CI: -0.74 to -0.38, P < 0.01) based on the Piper Fatigue Scale.
  • Subgroup analyses indicated distinct advantages of different acupuncture types.
  • Sensitivity analyses yielded unstable results, indicating potential publication bias.
  • Most outcomes were rated as low or very low quality according to GRADE criteria.
Interpretation:

While acupuncture may alleviate CRF, the evidence supporting its efficacy is limited, of low quality, and highlights significant gaps.

Limitations:
  • Methodological concerns in the included studies.
  • Low certainty of the available evidence.
  • Inconsistencies in study quality and acupoint selection.
  • Potential for publication bias.
Conclusion:

Further high-quality studies are needed to confirm the findings regarding acupuncture's efficacy in alleviating CRF.

Original Source(s)

Effectiveness of acupuncture for cancer-related fatigue: a systematic reviews and meta-analysis

  • by Hongxiao Zhang, Zhifeng Pan, Yuting Huang, Run Lin, Liying Wang, Tao Peng, Mingzhu Xu, Zining Guo, Shaoyang Cui

  • May 5, 2026

Related Content

This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar

Plus: NICE backs rozanolixizumab for uncontrolled gMG, Genexine reports SOX2 degrader data, and BeOne secures option on Huahui trispecific antibody

  • May 5, 2026

  • 5 min
COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

Zoldonrasib in Patients With <em>KRAS</em> G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy

The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were pr...